000131634 001__ 131634
000131634 005__ 20240228145611.0
000131634 0247_ $$2doi$$a10.1055/s-0043-121347
000131634 0247_ $$2pmid$$apmid:29212101
000131634 0247_ $$2ISSN$$a0044-2739
000131634 0247_ $$2ISSN$$a0044-2771
000131634 0247_ $$2ISSN$$a0172-8504
000131634 0247_ $$2ISSN$$a1439-7803
000131634 037__ $$aDKFZ-2017-06266
000131634 041__ $$aeng
000131634 082__ $$a610
000131634 1001_ $$0P:(DE-He78)4730a4e3dbc9057824efb4d2be729786$$aZhan, Tianzuo$$b0$$eFirst author$$udkfz
000131634 245__ $$aInvitation letters increase participation in colorectal cancer screening - results from an observational study.
000131634 260__ $$aStuttgart [u.a.]$$bThieme$$c2017
000131634 3367_ $$2DRIVER$$aarticle
000131634 3367_ $$2DataCite$$aOutput Types/Journal article
000131634 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1661255912_30405
000131634 3367_ $$2BibTeX$$aARTICLE
000131634 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131634 3367_ $$00$$2EndNote$$aJournal Article
000131634 520__ $$aBackground and Aim Participation rates in the German colorectal cancer screening program are low. Starting in 2013, a large health insurance plan in Bavaria, Germany, is sending an additional invitation letter to insured individuals when they turn 50 or 55 years and become eligible for participation in the program. The letter provides detailed information on colorectal cancer screening. We assessed the impact of the invitation letter on utilization rates. Methods Insurance claims data of a total of 48 343 individuals who had turned 50 or 55 years between 2012 to 2014 were reviewed for utilization rates of screening colonoscopy and fecal blood tests. Utilization rates 1 year prior (2012) and 2 years after introduction of the invitation letter (2013 and 2014) were compared. Furthermore, providers of colorectal cancer screening were determined. Results Within 6 months after turning 50 or 55 years, 8.8 - 10.2 % of all insured individuals participated in colorectal cancer screening, with the majority being females. After the introduction of the invitation letter, a moderate increase in participation rates could be observed (increase to 109 % [RR 101.7 - 117.3 %, p = 0.02] in 2014). The uptake rate of screening colonoscopy was significantly higher in recipients of the letter (increase to 138.4 % [RR 110.4 - 173.8 %, p = 0.0043] in 2013 and to 149 % [RR 119.5 - 186.3 %, p = 0.0003] in 2014). Furthermore, a significantly higher proportion of general practitioners and gastroenterologists provided colorectal cancer screening in individuals receiving the invitation letter. Conclusions Introduction of an invitation letter can improve participation rates for colorectal cancer screening.
000131634 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000131634 588__ $$aDataset connected to CrossRef, PubMed,
000131634 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1
000131634 7001_ $$aBilge, Asmé$$b2
000131634 7001_ $$aGiese, Thomas$$b3
000131634 7001_ $$aSchäfer, Christoph$$b4
000131634 7001_ $$aRiemann, Jürgen F$$b5
000131634 7001_ $$aEbert, Matthias P$$b6
000131634 7001_ $$aBelle, Sebastian$$b7
000131634 773__ $$0PERI:(DE-600)2041790-1$$a10.1055/s-0043-121347$$gVol. 55, no. 12, p. 1307 - 1312$$n12$$p1307 - 1312$$tZeitschrift für Gastroenterologie$$v55$$x1439-7803$$y2017
000131634 909CO $$ooai:inrepo02.dkfz.de:131634$$pVDB
000131634 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4730a4e3dbc9057824efb4d2be729786$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000131634 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000131634 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000131634 9141_ $$y2017
000131634 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bZ GASTROENTEROL : 2015
000131634 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131634 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131634 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000131634 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131634 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000131634 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131634 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131634 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000131634 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000131634 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000131634 9201_ $$0I:(DE-He78)B110-20160331$$kB110$$lB110 Signalwege funktionelle Genomik$$x0
000131634 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000131634 980__ $$ajournal
000131634 980__ $$aVDB
000131634 980__ $$aI:(DE-He78)B110-20160331
000131634 980__ $$aI:(DE-He78)C060-20160331
000131634 980__ $$aUNRESTRICTED